• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PCSK9 Inhibitors and Lipid Lowering: Viewpoint on Diabetic Retinopathy.

作者信息

Varughese Maria S, Nayak Ananth U

机构信息

Royal Hallamshire Hospital, University of Sheffield Medical School, Sheffield, United Kingdom.

University Hospitals of North Midlands NHS Trust, Stoke-on-Trent; School of Medicine, Faculty of Health, Keele University, North Staffordshire, United Kingdom.

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2025 Jan;56(1):62-63. doi: 10.3928/23258160-20241101-05. Epub 2024 Nov 1.

DOI:10.3928/23258160-20241101-05
PMID:39591622
Abstract
摘要

相似文献

1
PCSK9 Inhibitors and Lipid Lowering: Viewpoint on Diabetic Retinopathy.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂与降脂：关于糖尿病视网膜病变的观点
Ophthalmic Surg Lasers Imaging Retina. 2025 Jan;56(1):62-63. doi: 10.3928/23258160-20241101-05. Epub 2024 Nov 1.
2
Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.降胆固醇药物与糖尿病微血管并发症之间的因果关联：一项药物-靶点孟德尔随机化研究。
J Diabetes Res. 2025 Feb 28;2025:3661739. doi: 10.1155/jdr/3661739. eCollection 2025.
3
Association of lipid-lowering drugs with the risk of type 2 diabetes and its complications: a mendelian randomized study.降脂药物与2型糖尿病及其并发症风险的关联：一项孟德尔随机化研究
Diabetol Metab Syndr. 2024 Oct 4;16(1):240. doi: 10.1186/s13098-024-01477-8.
4
Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients.2 型糖尿病患者联合服用降血糖和调脂药物会进一步升高血浆 PCSK9 水平。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2087-2092. doi: 10.1016/j.dsx.2020.10.028. Epub 2020 Oct 30.
5
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
6
Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy.研究降脂药物与糖尿病视网膜病变并发症之间的关系。
Ophthalmic Surg Lasers Imaging Retina. 2024 Dec;55(12):706-713. doi: 10.3928/23258160-20240729-03. Epub 2024 Aug 1.
7
Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes.降脂药物与美国糖尿病患者视网膜病变和眼科干预风险降低相关。
Am J Ophthalmol. 2019 Nov;207:378-384. doi: 10.1016/j.ajo.2019.05.029. Epub 2019 Jun 10.
8
Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort.在心血管高危患者管理中使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂进行降脂治疗：真实世界队列中的有效性、治疗依从性和安全性
Cardiol J. 2018;25(1):32-41. doi: 10.5603/CJ.a2017.0137. Epub 2017 Nov 23.
9
PCSK9 Inhibitors in Multi-Branch Lesions in Coronary Artery Disease with Substandard Lipid-Lowering Effects.PCSK9 抑制剂在降脂效果不佳的冠心病多支病变中的应用。
Altern Ther Health Med. 2024 Aug;30(8):356-360.
10
Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies.脂质、高反射性结晶沉积物和糖尿病视网膜病变：降脂治疗的潜在全身和视网膜特异性作用。
Diabetologia. 2022 Apr;65(4):587-603. doi: 10.1007/s00125-022-05655-z. Epub 2022 Feb 11.

引用本文的文献

1
Hybrid closed loop and intensive insulin delivery technology: Reviewing the effect of improving 'time in range' glucose levels on diabetic retinopathy.混合闭环与强化胰岛素输注技术：探讨改善血糖处于目标范围内的时间对糖尿病视网膜病变的影响
Eye (Lond). 2025 Apr;39(6):1028-1030. doi: 10.1038/s41433-025-03730-4. Epub 2025 Feb 20.